Aderbasib

Aderbasib' (codenamed INCB7839) is a pharmacological compound classified as a sheddase inhibitor, which has been investigated for its potential to suppress tumor cell proliferation. Aderbasib targets multiple receptor classes and subclasses, specifically aiming to regulate the tumor necrosis factor associated with cancer cells, thereby impacting the growth and spread of tumors. Initially developed by Incyte, a biopharmaceutical company, Aderbasib was explored as a possible adjunctive treatment for metastatic breast cancer, among other potential cancer indications.

Pronunciation

Ad-er-ba-sib

Mechanism of Action

Aderbasib functions by inhibiting the activity of enzymes known as sheddases, which are involved in the process of shedding extracellular domains of various membrane-bound proteins. By blocking this process, Aderbasib aims to disrupt the signaling pathways that cancer cells use to grow, divide, and evade the immune system. This mechanism of action places it among a class of targeted therapies designed to interfere with specific molecules and receptors critical to tumor progression.

Clinical Development

Aderbasib's journey through clinical development included promising results from Phase II trials, which initially suggested its efficacy in reducing tumor cell proliferation in patients with metastatic breast cancer. However, the development of Aderbasib was halted in 2011. This decision followed subsequent research findings that contradicted the positive outcomes of earlier trials, raising questions about the drug's effectiveness and its role in cancer treatment protocols.

Implications of Development Halt

The discontinuation of Aderbasib's development reflects the complex and challenging nature of drug discovery and development, particularly in the field of oncology. The initial positive findings from early-phase trials underscore the potential that new therapeutic agents hold, yet the contradictory results of later studies highlight the uncertainties and risks inherent in the development process. This case exemplifies the critical need for rigorous and extensive research to fully understand the impacts and efficacy of novel treatments before they can be considered for widespread clinical use.

Related Terms

• Sheddase Inhibitor
• Tumor Necrosis Factor
• Metastatic Breast Cancer
• Cancer Treatment
• Drug Development

See Also

• Oncology
• Pharmacology
• Clinical Trials
• Targeted Therapy
• Incyte Corporation

External links

• Medical encyclopedia article on Aderbasib
• Wikipedia's article - Aderbasib

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski